HCPCS Level II Code Lookup

M

• M1304 Patient did not receive any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period
• M1305 Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period
• M1306 Patient had anaphylaxis due to the pneumococcal vaccine any time during or before the measurement period
• M1307 Documentation stating the patient has received or is currently receiving palliative or hospice care
• M1308 Influenza immunization was not administered, reason not given
• M1309 Palliative care services provided to patient any time during the measurement period
• M1310 Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user
• M1311 Anaphylaxis due to the vaccine on or before the date of the encounter
• M1312 Patient not screened for tobacco use
• M1313 Tobacco screening not performed or tobacco cessation intervention not provided during the measurement period or in the six months prior to the measurement period
• M1314 Bmi not documented and no reason is given
• M1315 Colorectal cancer screening results were not documented and reviewed; reason not otherwise specified
• M1316 Current tobacco non-user
• M1317 Patients who are counseled on connection with a csp and explicitly opt out
• M1318 Patients who did not have documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening or documentation that there was no contact with a csp
• M1319 Patients who had documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening
• M1320 Patients who screened positive for at least 1 of the 5 hrsns
• M1321 Patients who were not seen within 7 weeks following the date of injection for follow up or who did not have a documented iop or no plan of care documented if the iop was >25 mm hg
• M1322 Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop =<25 mm hg for injected eye
• M1323 Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop >25 mm hg and a plan of care was documented
• M1324 Patients who had an intravitreal or periocular corticosteroid injection (e.g., triamcinolone, preservative-free triamcinolone, dexamethasone, dexamethasone intravitreal implant, or fluocinolone intravitreal implant)
• M1325 Patients who were not seen for reasons documented by clinician for patient or medical reasons (e.g., inadequate time for follow-up, patients who received a prior intravitreal or periocular steroid injection within the last six (6) months and had a subsequent iop evaluation with iop <25mm hg within seven (7) weeks of treatment)
• M1326 Patients with a diagnosis of hypotony
• M1327 Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 8 weeks
• M1328 Patients with a diagnosis of acute vitreous hemorrhage
• M1329 Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 8 weeks after initial acute pvd encounter
• M1330 Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up)
• M1331 Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 8 weeks from initial exam
• M1332 Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 2 weeks
• M1333 Acute vitreous hemorrhage
• M1334 Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 2 weeks after initial acute pvd encounter
• M1335 Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up)
• M1336 Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 2 weeks
• M1337 Acute pvd
• M1338 Patients who had follow-up assessment 30 to 180 days after the index assessment who did not demonstrate positive improvement or maintenance of functioning scores during the performance period
• M1339 Patients who had follow-up assessment 30 to 180 days after the index assessment who demonstrated positive improvement or maintenance of functioning scores during the performance period
• M1340 Index assessment completed using the 12-item whodas 2.0 or sds during the denominator identification period
• M1341 Patients who did not have a follow-up assessment or did not have an assessment within 30 to 180 days after the index assessment during the performance period
• M1342 Patients who died during the performance period
• M1343 Patients who are at pam level 4 at baseline or patients who are flagged with extreme straight line response sets on the pam or with excessive missing responses
• M1344 Patients who did not have a baseline pam score and/or a second score within 4 to 12 months of baseline pam score
• M1345 Patients who had a baseline pam score and a second score within 4 to 12 month of baseline pam score
• M1346 Patients who did not have a net increase in pam score of at least 6 points within a 4 to 12 month period
• M1347 Patients who achieved a net increase in pam score of at least 3 points in a 4 to 12 month period (passing)
• M1348 Patients who achieved a net increase in pam score of at least 6-points in a 4 to 12 month period (excellent)
• M1349 Patients who did not have a net increase in pam score of at least 3 points within a 4 to 12 month period
• M1350 Patients who had a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter
• M1351 Patients who had a suicide safety plan initiated, reviewed, or updated and reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation
• M1352 Suicidal ideation and/or behavior symptoms based on the c-ssrs or equivalent assessment
• M1353 Patients who did not have a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter
• M1354 Patients who did not have a suicide safety plan initiated, reviewed, or updated or reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation
• M1355 Suicide risk based on their clinician's evaluation or a clinician-rated tool
• M1356 Patients who died during the measurement period
• M1357 Patients who had a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment
• M1358 Patients who did not have a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment
• M1359 Index assessment during the denominator period when the suicidal ideation and/or behavior symptoms or increased suicide risk by clinician determination occurs and a non-zero c-ssrs score is obtained
• M1360 Suicidal ideation and/or behavior symptoms based on the c-ssrs
• M1361 Suicide risk based on their clinician's evaluation or a clinician-rated tool
• M1362 Patients who died during the measurement period
• M1363 Patients who did not have a follow-up assessment within 120 days of the index assessment
• M1364 Calculated 10-year ascvd risk score of >= 20 percent during the performance period
• M1365 Patient encounter during the performance period with hospice and palliative care specialty code 17
• M1366 Focusing on women's health mips value pathway
• M1367 Quality care for the treatment of ear, nose, and throat disorders mips value pathway
• M1368 Prevention and treatment of infectious disorders including hepatitis c and hiv mips value pathway
• M1369 Quality care in mental health and substance use disorders mips value pathway
• M1370 Rehabilitative support for musculoskeletal care mips value pathway
• M1371 Most recent glycemic status assessment (hba1c or gmi) level < 7.0%
• M1372 Most recent glycemic status assessment (hba1c or gmi) level >= 7.0% and < 8.0%
• M1373 Most recent glycemic status assessment (hba1c or gmi) level >= 8.0% and <= 9.0%
• M1374 An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period
• M1375 An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period
• M1376 An additional encounter with an ra diagnosis during the performance period or prior performance period that is at least 90 days before or after an encounter with an ra diagnosis during the performance period
• M1377 Recommended follow-up interval for repeat colonoscopy of 10 years documented in colonoscopy report and communicated with patient
• M1378 Documentation of medical reason(s) for not recommending a 10 year follow-up interval (e.g., inadequate prep, familial or personal history of colonic polyps, patient had no adenoma and age is >= 66 years old, or life expectancy < 10 years, other medical reasons)
• M1379 A 10 year follow-up interval for colonoscopy not recommended, reason not otherwise specified
• M1380 Filled at least two prescriptions during the performance period for any combination of the qualifying oral antipsychotic medications listed under "denominator note" or the long-acting injectable antipsychotic medications listed under "denominator note"
• M1381 Patients with secondary stroke (e.g., a subsequent stroke that may occur with vasospasm in the setting of subarachnoid hemorrhage) within 5 days of the initial procedure
• M1382 Patient encounter during the performance period with place of service code 11
• M1383 Acute pvd
• M1384 Patients who died during the performance period
• M1385 Documentation of patient reasons for patients who were not seen for the second pam survey (e.g., less than four months between baseline pam assessment and follow-up
• M1386 Patients with an excisional surgery for melanoma or melanoma in situ in the past 5 years with an initial ajcc staging of 0, i, or ii at the start of the performance period
• M1387 Patients who died during the performance period
• M1388 Patients with documentation of an exam performed for recurrence of melanoma
• M1390 Patients who do not have a documented exam performed for recurrence of melanoma or no documentation within the performance period
• M1391 All patients who were diagnosed with recurrent melanoma during the current performance period
• M1392 Documentation of patient reasons for no examination, i.e., refusal of examination or lost to follow-up (documentation must include information that the clinician was unable to reach the patient by phone, mail or secure electronic mail - at least one method must be documented)
• M1393 Patients who were not diagnosed with recurrent melanoma during the current performance period
• M1394 Stages i-iii breast cancer
• M1395 Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
• M1396 Patients on a therapeutic clinical trial
• M1397 Patients with recurrence/disease progression
• M1398 Patients with baseline and follow-up promis surveys documented in the medical record
• M1399 Patients who leave the practice during the follow-up period
• M1400 Patients who died during the follow-up period
• M1401 Stages i-iii breast cancer
• M1402 Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
• M1403 Patients with baseline and follow-up promis surveys documented in the medical record
• M1404 Patients on a therapeutic clinical trial